International Journal of Drug Research and Technology

CARDIOMYOCYTES DERIVED FROM INDUCED PLURIPOTENT STEM CELLS FOR DRUG DEVELOPMENT

Abstract

Eliza Mac*

By providing platforms for studying the mechanisms of disease pathogenesis that could lead to new therapies or reveal drug sensitivities, induced pluripotent stem cell (iPSC) technology is creating exciting new opportunities for cardiovascular research. The potential applications of iPSC-derived cardiomyocytes in drug development and drug toxicity testing are examined in this review, with an emphasis on the accomplishments that have already been achieved in these areas. In addition, the essential actions that must be taken before this technology can be utilized extensively in drug discovery and toxicology evaluations are emphasized. The rapid adaptation of the technology to human cells and the discovery that somatic cells can be reprogrammed into pluripotent stem cells, which are capable of differentiating from all adult cell types, have led to high expectations regarding the potential applications.